Novartis' CEO said gene therapy is a 'nuanced puzzle' everyone is trying to figure out, but he's still committed to the cutting-edge treatments
Zolgensma has grown into a blockbuster, or a medicine that brings in over $1 billion in yearly revenue. Novartis expects sales to grow further with a tweaked version that's delivered into the spine.
Despite the success of Zolgensma, a driver of the $8.7 billion deal was the belief that AveXis could produce a series of gene therapies for several diseases, not just SMA. That hasn't happened; Narasimhan said one reason has to do with an unexpected finding related to how Zolgensma is delivered inside the body.
Zolgensma is ferried into cells by a type of engineered, hollowed-out virus called AAV9. Narasimhan said further research has found that AAV9 is"very good for neuromuscular diseases, but it doesn't penetrate the brain very well."that aimed to treat Rett syndrome, a rare genetic brain disorder. "I would say it's a solid success with Zolgensma," Narasimhan said, adding that his expectations for a tweaked version of the drug that's still being tested in older people with SMA would justify the $8.7 billion acquisition price."In order for it to be a spectacular success, we have to translate this now into a larger clinical-stage pipeline and ultimately launches in gene therapy, and there I'd say the jury is still out.
He described making each therapy as"a more nuanced puzzle you have to solve," particularly in choosing the right delivery tool to get into the desired cells.During its presentation at the conference, Novartis said it had 18 gene therapies in development, ranging from the earliest stages of development to early-to-mid-stage clinical studies.to acquire Gyroscope Therapeutics, a gene-therapy startup testing a treatment for a common cause of blindness.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novartis CEO Vas Narasimhan on future of gene therapy and ZolgensmaNovartis' CEO said gene therapy is a 'nuanced puzzle' everyone is trying to figure out, but he's still committed to the cutting-edge treatments
Read more »
Goldman Sachs bankers have nickname for layoff bloodbath planned by CEOWord of the layoffs by hard-charging Chief Executive David Solomon spread at the Wall Street giant’s headquarters in downtown Manhattan on Friday, sources said.
Read more »
SEC charges former McDonald's CEO Easterbrook with misleading investorsFormer McDonald's CEO Stephen Easterbrook has been charged by federal regulators with making false and misleading statements to investors about the circumstances of firing by the burger giant in November 2019.
Read more »
SEC fines ex-McDonald's CEO for misrepresenting his terminationThe SEC says a former McDonald's CEO who was fired for having an 'inappropriate personal relationship' with an employee will pay $400,000 over allegations that he misrepresented the cause behind his termination.
Read more »
Disney CEO Bob Iger orders employees back to office 4 days per weekThe new return-to-office plan reportedly takes effect on March 1.
Read more »
SEC charges McDonald’s ex-CEO with misrepresenting his 2019 firingThe SEC sued former McDonald's CEO Steve Easterbrook for misleading investors about inappropriate workplace relationships that led to his firing.
Read more »